Abstract
Neuroleptic malignant syndrome (NMS) was first described in the 1960s after the introduction of the dopamine receptor-blocking antipsychotic agents. Any drug with this pharmacologic profile, including the modern atypical antipsychotic agents and the antiemetic agent metoclopramide, can cause the typical syndrome consisting of all or some of the classical clinical features of hyperthermia, muscle rigidity, autonomic disturbance, and mental status changes. An almost identical syndrome, Parkinson-hyperpyrexia syndrome, can result from abrupt reduction or withdrawal of dopaminergic therapy in Parkinson’s disease patients. Although there are few formal studies assessing the efficacy of proposed treatments for NMS, bromocriptine and dantrolene are the most widely accepted medical treatments for this condition. Electroconvulsive therapy is useful in intractable cases. Most patients should be cared for in an ICU to adequately treat autonomic, respiratory, and renal complications. With treatment, most patients with NMS recover in 1–2 weeks, but recent surveys show an overall mortality of 5%.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Suggested Reading
Gilman PK. Neuroleptic malignant syndrome: mechanisms interactions and causality. Mov Disord. 2010;26:1780–90.
Langan J, Martin D, Shajahan P, Smith DJ. Antipsychotic dose escalation as a trigger for neuroleptic malignant syndrome (NMS): literature review and case series report. BMC Psychiatry. 2012;12:214–21.
Modi S, Dharaiya D, Schultz L, Varelas P. Neuroleptic malignant syndrome: complications. Outcomes and mortality. Neurocrit Care. 2016;24:97–103.
Pileggi DJ, Cook AM. Neuroleptic malignant syndrome review: focus on treatment and rechallenge. Ann Pharmacother. 2016; Epub ahead of print.
Saeki N, Kwon R, Migata T, Fukuda H, Hamada H, Kawamoto M. Electroconvulsive therapy using rocuronium and sugammadex in patient with neuroleptic malignant syndrome. Anestth Intensive Care. 2011;39:762–3.
Trollor JN, Chen X, Chitty K, Sachdev PS. Comparison of neuroleptic malignant syndrome induced by first- and second- generation antipsychotics. Br J Psychiatry. 2012;201:52–6.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Rodnitzky, R. (2019). Treatment of Neuroleptic Malignant Syndrome. In: Reich, S., Factor, S. (eds) Therapy of Movement Disorders. Current Clinical Neurology. Humana, Cham. https://doi.org/10.1007/978-3-319-97897-0_69
Download citation
DOI: https://doi.org/10.1007/978-3-319-97897-0_69
Published:
Publisher Name: Humana, Cham
Print ISBN: 978-3-319-97896-3
Online ISBN: 978-3-319-97897-0
eBook Packages: MedicineMedicine (R0)